Tevogen Bio Holdings Inc. has announced plans to relocate employees from its Philadelphia research and development center to its expanded principal executive offices in Warren, New Jersey. This move follows the expiration of the current lease in Philadelphia in June 2025. The relocation comes after Tevogen Bio Inc., a subsidiary of Tevogen Bio Holdings, amended its lease to double the office space at the New Jersey location and extend the lease term until February 2033.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.